10.0.3.140

VC backed Cadence Pharmaceuticals sells for $1.3bn

642
NYSE-listed pharmaceuticals company Mallinckrodt has agreed to acquire Nasdaq-listed Cadence Pharmaceuticals for $1.3bn.